BioStock: Chordate Medical got the ball rolling in the second quarter

At the beginning of the week, Chordate Medical published the report for the period January-June 2021. The most prominent achievement during the period was the CE marking for K.O.S for the treatment of chronic migraines – over a year earlier than the original plan – which led to the first commercial order for the migraine treatment system. The Medtech company now has an exciting autumn ahead with the ambition to establishing K.O.S on selected markets. In addition, the company aims to include the last patients in the ongoing migraine study with K.O.S.

Read the full article at biostock.se: 

https://www.biostock.se/en/2021/09/chordate-medical-got-the-ball-rolling-in-the-second-quarter/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se